Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 25 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Limitless Pharma from Antwerpen, company number BE0802144864, closed financial year 2025 with a result of € -18,605 after tax. For that financial year Limitless Pharma recorded a gross margin of € -18,071 and equity of € -22,918. Compared with financial year 2024, the result moved from € -11,314 to € -18,605. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 29, 2026.
€ -22,918
▼ € 13,605 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -18,605
▼ 64 % more loss than in 2024
Profit after tax over the fiscal year.
€ 1,208
▼ 53% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -29,918.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
€ 27,642
Loans from banks and other lenders, long and short.
€ 2,029
▼ 52% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € -10,186 | € -18,071 | ▼ € 7,886 |
| Profit after taxes | € -11,314 | € -18,605 | ▼ € 7,291 |
| Equity | € -9,314 | € -22,918 | ▼ € 13,605 |
| Total debts | € 31,985 | € 45,367 | ▲ 42% |
| Cash | € 2,553 | € 1,208 | ▼ 53% |
| Retained profit | € -11,314 | € -29,918 | ▼ € 18,605 |
| Bank debt | € 27,600 | € 27,642 | |
| Balance sheet total | € 22,671 | € 22,449 | ▼ 1% |
Key figures of Limitless Pharma, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Limitless Pharma?
What happened at Limitless Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 18,605. filed late Source: NBB ↗
- New establishment in Antwerpen. KBO
- Start of the company according to the CBE. KBO
- Louis Dellafaille became a director. NBB
In short
From € 11,314 loss in 2024 to € 18,605 loss in 2025.
A new publication or filing at Limitless Pharma? We notify you, reason included.
Follow Limitless PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Limitless Pharma is Louis Dellafaille. Louis Dellafaille is also behind Samre, LOUNIC, Luigi's, BAKKERIJ DELLAFAILLE and Jimmyz.
Establishments
Establishment units
Physical locations of this company
Merksemsesteenweg 196
2100 Antwerpen
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0802.144.864
- VAT number
- BE 0802.144.864
- Registered office
- Merksemsesteenweg 196, 2100 Antwerpen
- Names & denominations
- Limitless Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 May 2023
- Peppol
- Active · Active since 20 Sept 2026
- Activities · NACE
Overige niet-gespecialiseerde detailhandel
Detailhandel via postorderbedrijven of via internet